Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites the potential of the company’s lead commercial drug, Zepzelca targeting small cell lung cancer, to obtain additional regulatory approvals, significantly increasing its addressable market for the Buy rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHMMF: